Ustekinumab Subcutaneous and Venclexta Starting Pack
Determining the interaction of Ustekinumab Subcutaneous and Venclexta Starting Pack and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using ustekinumab together with venetoclax may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: The use of ustekinumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious bacterial, fungal, and viral infections have been observed during clinical trials with ustekinumab, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (greater than 10 mg/day to 1 mg/kg/day, whichever is less, of prednisone or equivalent for more than 2 weeks), and long-term topical or inhaled corticosteroids.
MANAGEMENT: Caution is advised if ustekinumab must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy.
- "Product Information. Stelara (ustekinumab)." Centocor Inc, Malvern, PA.
Generic Name: ustekinumab
Brand name: Stelara, Stelara PFS
Synonyms: Ustekinumab (Subcutaneous)
Generic Name: venetoclax
Brand name: Venclexta, Venclexta Starting Pack
Synonyms: Venclexta
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ustekinumab Subcutaneous-Venetoclax
- Ustekinumab Subcutaneous-Venipuncture CPI
- Ustekinumab Subcutaneous-Venipuncture PX1
- Ustekinumab Subcutaneous-Venlafaxine
- Ustekinumab Subcutaneous-Venlafaxine ER
- Ustekinumab Subcutaneous-Venlafaxine ER Capsules
- Venclexta Starting Pack-Ustekinumab Subcutaneous Injection
- Venclexta Starting Pack-Ustell
- Venclexta Starting Pack-UTA
- Venclexta Starting Pack-UTA Capsules
- Venclexta Starting Pack-UTAC tablets
- Venclexta Starting Pack-UTI Relief